ClinicalTrials.gg
CompletedNCT02276482Updated Aug 7, 2019Results posted

Study of Tedizolid Phosphate in Adolescents With Complicated Skin and Soft Tissue Infection (cSSTI) (MK-1986-012)

A Phase 3 interventional study of Tedizolid Phophate and Antibiotic comparator in Skin Diseases, Infectious and Skin Diseases, Bacterial, sponsored by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). Completed. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2019-08-07.

Primary conditionSkin Diseases, BacterialRegistry: Skin Diseases, InfectiousReclassifiedWhy we changed it
Registry
Skin Diseases, Infectious — the first condition term the registry derived for this study.
ClinicalTrials.gg
Skin Diseases, Bacterial
Why
  1. The study's listed conditions name Skin Diseases, Bacterial, a narrower term within Skin Diseases, Infectious.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Study summary

The purpose of the study is to compare the safety of intravenous (IV) and/or oral 6-day 200 mg tedizolid phosphate with 10-day comparator in participants 12 to \<18 years with cSSTI.

Read the detailed description

A randomized, single-blind, multicenter, Phase 3 study of IV and/or oral tedizolid phosphate 200 mg once per day for 6 days compared with IV and/or oral comparator for 10 days for the treatment of cSSTI, also known as acute bacterial skin and skin structure infections, in participants 12 to \<18 years. cSSTI includes major cutaneous abscess, cellulitis/erysipelas, and wound infection.

02

Conditions studied

  • Skin Diseases, Infectious
  • Skin Diseases, Bacterial

Browse trials for

03

In context

Skin Diseases, Bacterial Reclassified

37 studies on the registry are indexed under Skin Diseases, Bacterial; 2 are open to participants now.

This study's enrollment of 120 is below the median of 249 across 29 interventional studies indexed under Skin Diseases, Bacterial.

Browse Skin Diseases, Bacterial studies →

Lead sponsor

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) is the lead sponsor of 65 studies on the registry; none are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.

First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc.

Compared within Skin Diseases, Bacterial, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Skin Diseases, Infectious. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females 12 years to \<18 years
  • Adequate venous access for IV administration of study drug for at least 24 hours (for participants receiving IV medication) and collection of protocol-specified blood samples
  • Local symptoms must have started within 7 days before Study Day -1
  • cSSTI meeting at least 1 of the clinical syndrome definitions.
  • Suspected or documented Gram-positive infection from baseline Gram stain or culture.
  • Parent/legally authorized representative (LAR) able to give and willing and able to comply with all required study procedures. Assent is also required of children who in the Investigator's judgment are capable of understanding the nature of the study

Exclusion criteria

Exclusion Criteria:

  • Uncomplicated minor skin and skin structure infections such as pustules, folliculitis, furuncles, minor abscesses (small volume of suppuration not surrounded by cellulitis/erysipelas), impetiginous lesions, superficial or limited cellulitis/erysipelas, and minor wound associated foreign body reactions (eg, stitch abscesses)
  • Known bacteremia, severe sepsis or septic shock
  • Recent history of opportunistic infections where the underlying cause of these infections is still active (eg, leukemia, transplant, acquired immunodeficiency syndrome)
  • to tedizolid phosphate or any component in the formulation
  • Hypersensitivity to all of the comparator drugs; hypersensitivity to a comparator drug does not preclude participation if an alternative comparator can be used
  • For participants with wound infections: history of hypersensitivity to ceftazidime, aztreonam, or any component of the aztreonam formulation, if aztreonam adjunctive therapy is required; history of hypersensitivity to metronidazole or any component of the formulation, if metronidazole adjunctive therapy is required
  • Needs oral administration of methotrexate, topotecan, irinotecan or rosuvastatin, during administration of oral study drug.
  • Uses monoamine oxidase inhibitors, tricyclic antidepressants, buspirone, selective serotonin reuptake inhibitors and serotonin 5 hydroxytryptamine receptor agonists (triptans) within 14 days prior to study drug administration
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    Tedizolid Phosphate

    Tedizolid Phosphate IV and/or oral 200 mg once per day for 6 days. Participants with gram-negative wound infection may receive aztreonam (IV) and/or metronidazole (IV or oral).

    Drug: Tedizolid Phophate · Drug: Aztreonam · Drug: Metronidazole

  • Active comparator
    Antibiotic comparator drug

    IV and/or oral antibiotic comparator drug for 10 days. Participants with gram-negative wound infection may receive aztreonam (IV) and/or metronidazole (IV or oral).

    Drug: Antibiotic comparator · Drug: Aztreonam · Drug: Metronidazole

Interventions

  • Tedizolid Phophate 200 mg, IV and/or oral for 6 days

    Also known as: TR701-122, MK-1986, SIVEXTRO®

  • DrugAntibiotic comparator

    Antibiotic comparator drug, IV and/or orally for 10 days. Antibiotic comparator included the following: Vancomycin, Linezolid, Clindamycin, Flucloxacillin, Cefazolin, Cephalexin.

    Also known as: Vancomycin: Vancocin, Firvanq, Lyphocin; Linezolid: Zyvox; Clindamycin: Cleocin; Flucloxacillin: Floxapen, Flopen, Staphylex; Cefazolin: Ancef, Kefzol; Cephalexin: Keflex, Zartan, Panixine, Biocef

  • In countries and/or sites where aztreonam is available, adjunctive aztreonam (IV) may be initiated on Day 1 or during the first 3 days of treatment if the participant is determined or suspected to have an infection with gram-negative aerobic pathogens.

    Also known as: Azactam, Cayston

  • Metronidazole (IV or oral) may be initiated on Day 1 or during the first 3 days of treatment if the participant is determined or suspected to have an infection with anaerobic pathogens.

    Also known as: Flagyl, Metro

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events on Tedizolid Phosphate and Comparator Drugs

    An adverse event (AE) refers to a treatment-emergent adverse event (TE-AE). A TE-AE is any AE that newly appeared, increased in frequency, or worsened in severity following initiation of study drug.

    Time frame: Up to 40 days (including 30-day follow-up)

Secondary outcomes

  1. Number of Participants With Investigator's Assessment Indicating Clinical Success at Test of Cure (TOC) Visit (Intent to Treat Analysis Set)

    Investigator's assessment of clinical success is defined as (1) resolution or near resolution of most disease-specific signs and symptoms, (2)absence or near resolution of regional or systemic signs of infection (lymphadenopathy, fever, \>10% immature neutrophils, abnormal white blood cell count), if present at baseline, and (3) no new signs, symptoms, or complications attributable to the infection under study so no further antibiotic therapy is required for the treatment of the primary lesion.

    Time frame: TOC Visit: 18-25 days after first drug infusion

  2. Number of Participants With Investigator's Assessment Indicating Clinical Success at TOC Visit (Clinically Evaluable-Test of Cure [CE-TOC] Analysis Set)

    Investigator's assessment of clinical success is defined as (1) resolution or near resolution of most disease-specific signs and symptoms, (2)absence or near resolution of regional or systemic signs of infection (lymphadenopathy, fever, \>10% immature neutrophils, abnormal white blood cell count), if present at baseline, and (3) no new signs, symptoms, or complications attributable to the infection under study so no further antibiotic therapy is required for the treatment of the primary lesion.

    Time frame: TOC Visit: 18-25 days after first drug infusion

  3. Number of Participants With Early Clinical Responses Measured by Lesion Reduction

    Early clinical response is defined as ≥20% reduction from baseline lesion area (defined as length multiplied by the width of the erythema, edema, and/or induration \[EEI\]) at the 48-72 hour (hr) visit.

    Time frame: 48-72 hr after first drug infusion

  4. Number of Participants With Investigator's Assessment Indicating Clinical Success at End of Therapy (EOT) Visit (Intent to Treat Analysis Set)

    Investigator's assessment of clinical success is defined as (1) resolution or near resolution of most disease-specific signs and symptoms, (2)absence or near resolution of regional or systemic signs of infection (lymphadenopathy, fever, \>10% immature neutrophils, abnormal white blood cell count), if present at baseline, and (3) no new signs, symptoms, or complications attributable to the infection under study so no further antibiotic therapy is required for the treatment of the primary lesion.

    Time frame: EOT Visit: up to 13 days after first drug infusion

  5. Number of Participants With Investigator's Assessment Indicating Clinical Success at EOT Visit (Clinically Evaluable-End of Therapy [CE-EOT] Analysis Set)

    Investigator's assessment of clinical success is defined as (1) resolution or near resolution of most disease-specific signs and symptoms, (2) absence or near resolution of regional or systemic signs of infection (lymphadenopathy, fever, \>10% immature neutrophils, abnormal white blood cell count), if present at baseline, and (3) no new signs, symptoms, or complications attributable to the infection under study so no further antibiotic therapy is required for the treatment of the primary lesion.

    Time frame: EOT Visit: up to 13 days after first drug infusion

Other outcomes

  1. Change From Baseline in Lesion Size

    Lesion size is the area in cm\^2 of erythema, edema or induration. A negative number corresponds to a decrease in lesion size.

    Time frame: Baseline and TOC visit (18 to 25 days after infusion)

  2. Peak Plasma Concentration (Cmax) of Tedizolid

    The Cmax of tedizolid in plasma after the last dose was estimated based on population pharmacokinetic analysis of observed pharmacokinetic data. Blood samples were collected for pharmacokinetic analysis at specific time points.

    Time frame: Day 1 at 5-80 minutes (min) and 4-12 hrs post-infusion or 2 samples collected between 4-12 hrs after oral dose, at least 60 min apart; at 48-72 hrs: within 60 min prior to administration and 4-12 hrs after administration; and anytime between Day 7 and 9

  3. Area Under the Plasma Concentration Versus Time Curve Time 0 to 24 Hours (AUC0-24h) of Tedizolid

    AUC0-24h is a measure of the total tedizolid exposure in the plasma from the dose to 24 hours after last dose. AUC0-24h was estimated based on population pharmacokinetic analysis of observed pharmacokinetic data. Blood samples were collected for pharmacokinetic analysis at specific time points.

    Time frame: Day 1 at 5-80 min and 4-12 hrs post-infusion or 2 samples collected between 4-12 hrs after oral dose, at least 60 min apart; at 48-72 hrs: within 60 min prior to administration and 4-12 hrs after administration; and anytime between Day 7 and 9

07

Results

Posted Aug 7, 2019

Participant flow

Participant flow — Overall Study
MilestoneTedizolid PhosphateAntibiotic Comparator Drug
Started9129
Completed8828
Not completed31
Withdrew: Adverse event10
Withdrew: Withdrawal by subject10
Withdrew: Gram-negative infection10
Withdrew: Reason not specified01

Outcome measures

PrimaryNumber of Participants With Adverse Events on Tedizolid Phosphate and Comparator Drugs

An adverse event (AE) refers to a treatment-emergent adverse event (TE-AE). A TE-AE is any AE that newly appeared, increased in frequency, or worsened in severity following initiation of study drug.

Time frame:
Up to 40 days (including 30-day follow-up)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events on Tedizolid Phosphate and Comparator Drugs
ParticipantsTedizolid PhosphateAntibiotic Comparator Drug
Number of Participants With Adverse Events on Tedizolid Phosphate and Comparator Drugs133
SecondaryNumber of Participants With Investigator's Assessment Indicating Clinical Success at Test of Cure (TOC) Visit (Intent to Treat Analysis Set)

Investigator's assessment of clinical success is defined as (1) resolution or near resolution of most disease-specific signs and symptoms, (2)absence or near resolution of regional or systemic signs of infection (lymphadenopathy, fever, \>10% immature neutrophils, abnormal white blood cell count), if present at baseline, and (3) no new signs, symptoms, or complications attributable to the infection under study so no further antibiotic therapy is required for the treatment of the primary lesion.

Time frame:
TOC Visit: 18-25 days after first drug infusion
Reported as:
Count of participants · Participants
Number of Participants With Investigator's Assessment Indicating Clinical Success at Test of Cure (TOC) Visit (Intent to Treat Analysis Set)
ParticipantsTedizolid PhosphateAntibiotic Comparator Drug
Number of Participants With Investigator's Assessment Indicating Clinical Success at Test of Cure (TOC) Visit (Intent to Treat Analysis Set)8827
Statistical analysis
  • Tedizolid Phosphate vs Antibiotic Comparator Drug · Difference in percentages: 3.6 · 95% CI -6.3 to 13.5The difference (Tedizolid minus Comparator group) in the clinical success rate and 95% confidence interval calculated using the unstratified method of Miettinen and Nurminen.
SecondaryNumber of Participants With Investigator's Assessment Indicating Clinical Success at TOC Visit (Clinically Evaluable-Test of Cure [CE-TOC] Analysis Set)

Investigator's assessment of clinical success is defined as (1) resolution or near resolution of most disease-specific signs and symptoms, (2)absence or near resolution of regional or systemic signs of infection (lymphadenopathy, fever, \>10% immature neutrophils, abnormal white blood cell count), if present at baseline, and (3) no new signs, symptoms, or complications attributable to the infection under study so no further antibiotic therapy is required for the treatment of the primary lesion.

Time frame:
TOC Visit: 18-25 days after first drug infusion
Reported as:
Count of participants · Participants
Number of Participants With Investigator's Assessment Indicating Clinical Success at TOC Visit (Clinically Evaluable-Test of Cure [CE-TOC] Analysis Set)
ParticipantsTedizolid PhosphateAntibiotic Comparator Drug
Number of Participants With Investigator's Assessment Indicating Clinical Success at TOC Visit (Clinically Evaluable-Test of Cure [CE-TOC] Analysis Set)8726
Statistical analysis
  • Tedizolid Phosphate vs Antibiotic Comparator Drug · Difference in percentages: 3.7 · 95% CI -3.4 to 10.8The difference (Tedizolid minus Comparator group) in the clinical success rate and 95% confidence interval calculated using the unstratified method of Miettinen and Nurminen.
SecondaryNumber of Participants With Early Clinical Responses Measured by Lesion Reduction

Early clinical response is defined as ≥20% reduction from baseline lesion area (defined as length multiplied by the width of the erythema, edema, and/or induration \[EEI\]) at the 48-72 hour (hr) visit.

Time frame:
48-72 hr after first drug infusion
Reported as:
Count of participants · Participants
Number of Participants With Early Clinical Responses Measured by Lesion Reduction
ParticipantsTedizolid PhosphateAntibiotic Comparator Drug
Number of Participants With Early Clinical Responses Measured by Lesion Reduction8428
Statistical analysis
  • Tedizolid Phosphate vs Antibiotic Comparator Drug · Difference in percentages: -4.2 · 95% CI -12.9 to 4.4The difference (Tedizolid minus Comparator group) in the clinical success rate and 95% confidence interval calculated using the unstratified method of Miettinen and Nurminen.
SecondaryNumber of Participants With Investigator's Assessment Indicating Clinical Success at End of Therapy (EOT) Visit (Intent to Treat Analysis Set)

Investigator's assessment of clinical success is defined as (1) resolution or near resolution of most disease-specific signs and symptoms, (2)absence or near resolution of regional or systemic signs of infection (lymphadenopathy, fever, \>10% immature neutrophils, abnormal white blood cell count), if present at baseline, and (3) no new signs, symptoms, or complications attributable to the infection under study so no further antibiotic therapy is required for the treatment of the primary lesion.

Time frame:
EOT Visit: up to 13 days after first drug infusion
Reported as:
Count of participants · Participants
Number of Participants With Investigator's Assessment Indicating Clinical Success at End of Therapy (EOT) Visit (Intent to Treat Analysis Set)
ParticipantsTedizolid PhosphateAntibiotic Comparator Drug
Number of Participants With Investigator's Assessment Indicating Clinical Success at End of Therapy (EOT) Visit (Intent to Treat Analysis Set)8828
Statistical analysis
  • Tedizolid Phosphate vs Antibiotic Comparator Drug · Difference in percentages: 0.2 · 95% CI -7.4 to 7.7The difference (Tedizolid minus Comparator group) in the clinical success rate and 95% confidence interval calculated using the unstratified method of Miettinen and Nurminen.
SecondaryNumber of Participants With Investigator's Assessment Indicating Clinical Success at EOT Visit (Clinically Evaluable-End of Therapy [CE-EOT] Analysis Set)

Investigator's assessment of clinical success is defined as (1) resolution or near resolution of most disease-specific signs and symptoms, (2) absence or near resolution of regional or systemic signs of infection (lymphadenopathy, fever, \>10% immature neutrophils, abnormal white blood cell count), if present at baseline, and (3) no new signs, symptoms, or complications attributable to the infection under study so no further antibiotic therapy is required for the treatment of the primary lesion.

Time frame:
EOT Visit: up to 13 days after first drug infusion
Reported as:
Count of participants · Participants
Number of Participants With Investigator's Assessment Indicating Clinical Success at EOT Visit (Clinically Evaluable-End of Therapy [CE-EOT] Analysis Set)
ParticipantsTedizolid PhosphateAntibiotic Comparator Drug
Number of Participants With Investigator's Assessment Indicating Clinical Success at EOT Visit (Clinically Evaluable-End of Therapy [CE-EOT] Analysis Set)8727
Statistical analysis
  • Tedizolid Phosphate vs Antibiotic Comparator Drug · Difference in percentages: 0.0 · 95% CI 0.0 to 0.0The difference (Tedizolid minus Comparator group) in the clinical success rate and 95% confidence interval calculated using the unstratified method of Miettinen and Nurminen.
Other pre-specifiedChange From Baseline in Lesion Size

Lesion size is the area in cm\^2 of erythema, edema or induration. A negative number corresponds to a decrease in lesion size.

Time frame:
Baseline and TOC visit (18 to 25 days after infusion)
Reported as:
Mean · cm^2
Change From Baseline in Lesion Size
cm^2Tedizolid PhosphateAntibiotic Comparator Drug
Baseline135.44 ± 158.6683.22 ± 48.55
Change at Day 25-134.27 ± 161.18-82.51 ± 49.94
Other pre-specifiedPeak Plasma Concentration (Cmax) of Tedizolid

The Cmax of tedizolid in plasma after the last dose was estimated based on population pharmacokinetic analysis of observed pharmacokinetic data. Blood samples were collected for pharmacokinetic analysis at specific time points.

Time frame:
Day 1 at 5-80 minutes (min) and 4-12 hrs post-infusion or 2 samples collected between 4-12 hrs after oral dose, at least 60 min apart; at 48-72 hrs: within 60 min prior to administration and 4-12 hrs after administration; and anytime between Day 7 and 9
Reported as:
Geometric mean · µg/mL
Peak Plasma Concentration (Cmax) of Tedizolid
µg/mLTedizolid PhosphateAntibiotic Comparator Drug
Peak Plasma Concentration (Cmax) of Tedizolid3.13 (2.89 to 3.38)—
Other pre-specifiedArea Under the Plasma Concentration Versus Time Curve Time 0 to 24 Hours (AUC0-24h) of Tedizolid

AUC0-24h is a measure of the total tedizolid exposure in the plasma from the dose to 24 hours after last dose. AUC0-24h was estimated based on population pharmacokinetic analysis of observed pharmacokinetic data. Blood samples were collected for pharmacokinetic analysis at specific time points.

Time frame:
Day 1 at 5-80 min and 4-12 hrs post-infusion or 2 samples collected between 4-12 hrs after oral dose, at least 60 min apart; at 48-72 hrs: within 60 min prior to administration and 4-12 hrs after administration; and anytime between Day 7 and 9
Reported as:
Geometric mean · µg*h/mL
Area Under the Plasma Concentration Versus Time Curve Time 0 to 24 Hours (AUC0-24h) of Tedizolid
µg*h/mLTedizolid PhosphateAntibiotic Comparator Drug
Area Under the Plasma Concentration Versus Time Curve Time 0 to 24 Hours (AUC0-24h) of Tedizolid28.6 (26.6 to 30.8)—

Adverse events

Collected over Up to 40 days (including 30-day follow-up). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tedizolid Phosphate0/91 (0%)1/91 (1.1%)0/91 (0%)
Antibiotic Comparator Drug0/29 (0%)0/29 (0%)0/29 (0%)
Most frequent serious events
Most frequent serious events
EventTedizolid PhosphateAntibiotic Comparator Drug
PneumoniaInfections and infestations1/910/29
SepsisInfections and infestations1/910/29
Venous Thrombosis LimbVascular disorders1/910/29

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Tedizolid PhosphateAntibiotic Comparator DrugTotal
Mean14.4 ± 1.714.4 ± 2.014.4 ± 1.7
Sex: Female, Male
Sex: Female, Male(Participants)Tedizolid PhosphateAntibiotic Comparator DrugTotal
Female331245
Male581775
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Tedizolid PhosphateAntibiotic Comparator DrugTotal
Hispanic or Latino415
Not Hispanic or Latino8628114
Unknown or Not Reported101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Tedizolid PhosphateAntibiotic Comparator DrugTotal
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American11415
White8024104
More than one race000
Unknown or Not Reported000
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Bradley JS, Antadze T, Ninov B, Tayob MS, Broyde N, Butterton JR, Chou MZ, De Anda CS, Kim JY, Sears PS. Safety and Efficacy of Oral and/or Intravenous Tedizolid Phosphate From a Randomized Phase 3 Trial in Adolescents With Acute Bacterial Skin and Skin Structure Infections. Pediatr Infect Dis J. 2021 Mar 1;40(3):238-244. doi: 10.1097/INF.0000000000003010. PubMed 33395210 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2015 to primary completion in Sep 2018, 41 months.

Results were first posted in Aug 2019, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2014
First posted
Oct 28, 2014
StartActual
Mar 25, 2015
Primary completionActual
Sep 17, 2018
CompletionActual
Sep 17, 2018
Results first posted
Aug 7, 2019
Last update
Aug 7, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02276482
Responsible party
Sponsor
First posted
Oct 28, 2014
Start date
Mar 25, 2015
Primary completion
Sep 17, 2018
Completion
Sep 17, 2018
Results posted
Aug 7, 2019
Last update
Aug 7, 2019

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tedizolid phosphate

Start the discussion